For a target gene, our pipeline designs and ranks antisense oligonucleotide candidates across four upregulation mechanisms: splice-switching at poison/cassette exons (TANGO), alternative splice-site extensions, AntagoNAT gapmers against natural antisense transcripts, and cis-element blockers. Each candidate is scored on medicinal-chemistry quality, target-site accessibility, specificity (off-target alignment), and brain expression, then assembled into a diversified screening plate with an automated discovery briefing. Select a featured disease gene below. Looking for small molecules instead? See the repurposing explorer and drug design dashboard.

Have a haploinsufficiency target?

We design, rank, and de-risk ASO candidates for upregulation targets, including ultrarare disorders that are underserved by industry. Tell us your gene and we will run the pipeline and share a shortlist.

Contact us about an ASO program
References (tools used in the upstream ASO design pipeline)
Colombo M, et al. NMDtxDB: data-driven identification and annotation of human NMD target transcripts. RNA 2024;30(10):1277-1290.
GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 2020;369(6509):1318-1330.
Pollard KS, et al. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res 2010;20(1):110-121.
Bernhart SH, et al. Local RNA base pairing probabilities in large sequences. Bioinformatics 2006;22(5):614-615.
Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012;9(4):357-359.